Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STXS
STXS logo

STXS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

STXS News

Stereotaxis Receives FDA Clearance for Synchrony System Launch

1d agoseekingalpha

Stereotaxis Receives FDA Clearance for Synchrony System

1d agoNASDAQ.COM

Stereotaxis Secures FDA 510(k) Clearance for Synchrony System

1d agoNASDAQ.COM

Stereotaxis Receives FDA Clearance for Synchrony System

1d agoNewsfilter

DAFNA Capital Management Reduces Stake in Biotechnology ETF

Mar 21 2026NASDAQ.COM

DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF

Mar 21 2026Fool

Stereotaxis Reports 36% Revenue Growth in Q4

Mar 10 2026Yahoo Finance

Stereotaxis Q4 2025 Earnings Call Insights

Mar 10 2026seekingalpha

STXS Events

04/06 08:20
Stereotaxis Receives FDA 510(k) Clearance for Synchrony System
Stereotaxis announced that it has received FDA 510(k) clearance for the Synchrony system. "Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with enhanced workflow, remote connectivity, and smart AI capabilities," said David Fischel Stereotaxis chairman and CEO. "The technology improves the robotic cockpit, and will be critical in supporting robotic efforts for remote long-distance procedures and automated catheter navigation. The opportunity is much broader than robotic labs as we believe all cath labs stand to benefit from improved workflow, connectivity, and collaboration."
03/09 16:10
Company Reports Q4 Revenue of $8.64M
Reports Q4 revenue $8.64M, consensus $9.24M. System backlog at the start of 2026 is $9.1M. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, chairman and CEO.

STXS Monitor News

No data

No data

STXS Earnings Analysis

Stereotaxis Reports Third Quarter 2024 Financial Results
1 years ago

People Also Watch